Gelest Inc. Overview
Gelest is a niche, technology-led US manufacturer of specialty organosilicon and metal-organic chemistry — silanes, reactive silicones, metal-organic compounds and (since the 2019 Bimax acquisition) specialty acrylate monomers. Its model combines a very broad research-quantity catalogue, reported to run to several thousand materials, with scale-up and commercial manufacturing for customers who design Gelest molecules into their own products. End markets are high-value and qualification-intensive: semiconductor and microelectronics precursors, medical devices and vision care (contact and intraocular lens monomers), life sciences and diagnostics, pharmaceutical synthesis, personal care, and advanced coatings and adhesives. Since 2020 it has operated as Mitsubishi Chemical Group's US research-and-custom-synthesis hub, described by the parent as a research excellence centre. Its most visible strategic bet is metal-organic precursors for Lam Research's EUV dry-resist lithography, supported by a new 50,000 sq ft Morrisville production building opened in May 2025 and a 2026 test collaboration with IBM on High-NA EUV.
What the company does
Gelest develops, manufactures and sells specialty chemicals built on silicon–carbon, silicon–oxygen and metal–ligand chemistry. Its own corporate description (Gelest/Nordmann press release, December 2025) positions it as a developer and manufacturer of specialty acrylates, silanes, silicones and metal-organic compounds serving four advanced end markets: electronics and semiconductors, medical and life sciences, aerospace and defence, and advanced manufacturing. An earlier self-description (CHEManager company profile) lists medical devices, life sciences, coatings and adhesives, microelectronics and personal care, and emphasises access to Mitsubishi Chemical Group R&D and resources.
The company's historic positioning statement — the "Enabling Your Technology" tagline used in its 2017 New Mountain Capital announcement — captures the operating model: Gelest's chemists co-develop molecules with customers' R&D teams, supply research quantities from catalogue, and then scale successful molecules into commercial production at its own plants. A third-party profile reproducing older company copy says joint development with customers expanded the product listing from several hundred materials to several thousand.
Business and revenue model
| Revenue stream | Description | Disclosed mix |
|---|---|---|
| Catalogue / research-quantity sales | Gram-to-kilogram sales of thousands of silanes, silicones, metal-organics and monomers to academic, government and corporate labs | — |
| Commercial-scale specialty product sales | Larger-volume supply of qualified molecules (e.g., coupling agents, reactive silicone fluids, lens monomers, precursors) to OEM/formulator customers | — |
| Custom synthesis / contract manufacturing | Customer-specific molecules made under supply agreements; Gelest's president was also titled Vice President of MCG's Custom Synthesis Division in 2023 | — |
| Electronic-grade precursors | High-purity metal-organic and organosilicon precursors for deposition and EUV dry resist, made in a facility with an ISO 7 cleanroom | — |
| Licensing / subscription | No licensing or subscription revenue identified | — |
The business is essentially 100% product revenue; there is no evidence of service, subscription or licensing income. Distribution is direct in North America, with distributors elsewhere — most recently Nordmann as primary EMEA distributor from 1 January 2026 and in India from February 2026.
Value-chain position
Gelest sits in the mid-to-downstream specialty layer of the silicon chemistry value chain. It does not operate upstream silicon-metal or methylchlorosilane "direct process" production (the domain of Dow, Wacker, Shin-Etsu, Momentive, Elkem). Instead it buys or synthesises intermediates and performs higher-value functionalisation, purification, polymerisation and surface treatment. In semiconductors, it is a materials supplier to equipment makers and fabs (e.g., precursor supplier within Lam Research's dry-resist ecosystem) rather than an equipment or resist-process owner.
Customer types and end markets
| End market | Typical Gelest offering | Evidence |
|---|---|---|
| Semiconductors / microelectronics | ALD/CVD precursors, EUV dry-resist metal-organic precursors, volatile higher silanes | Lam/Entegris collaboration (Jul 2022); IBM agreement (Feb 2026); 2022 CVD research publications |
| Medical devices & vision care | Silicone and acrylate monomers for contact lenses and intraocular lenses; medical-grade silicones | Bimax acquisition coverage (CHEManager, Jul 2019); MCA statement citing vision care |
| Life sciences, diagnostics, separation science | Surface-modification silanes for chromatography and diagnostic substrates | New Mountain portfolio description |
| Pharmaceutical synthesis | Silylating agents, bulk metal-organics used as reagents/catalysts | Gelest website (bulk metal-organics and silanes for pharma) |
| Personal care | Specialty silicones and monomers | MCC 2020 release; Bimax |
| Coatings, adhesives, sealants, composites | Industrial coupling silanes, epoxy-modifying silanes and silicones, antimicrobial silane quats | Gelest website; India/Nordmann coatings focus |
| Aerospace & defence, advanced manufacturing, mobility, thermal coatings | Specialty silicones and silanes | Nordmann release (Dec 2025); 2023 groundbreaking release |
Independent characterisation
Gelest is best understood as a high-mix, low-volume, high-margin specialty house whose moat is chemistry breadth, technical service and qualification lock-in rather than scale. Its founder's reputation (Barry Arkles is a widely cited authority on silane coupling agents) and its technical literature have historically functioned as the primary marketing channel. Under Mitsubishi ownership, the strategic centre of gravity has shifted measurably toward semiconductor precursors — the only area in which Gelest has announced a dedicated capital project and named external technology partners in the last four years. The medical/vision-care franchise (Bimax) and the broad catalogue business provide the cash base. The principal analytical limitation is that none of these franchises can be sized from public data.
Strategy
Stated strategy
Gelest publishes no annual report. Its strategic themes, paraphrased from releases since 2020, are: (1) helping customers solve hard materials-science problems by co-developing and supplying chemistry for their new products; (2) using MCG's resources and customer network to commercialise Gelest technologies faster, with MCA's president naming digital social infrastructure, vision care and life sciences as the priority areas in 2020; (3) expanding US capacity for critical advanced-manufacturing materials, explicitly tied to on-shoring and US supply-chain resilience (2023); and (4) focusing incremental capacity on microelectronics, especially EUV dry-resist precursors (2025).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| New production building | Opened May 2025 | Capacity for microelectronics, medical devices, thermal coatings, mobility; main focus on dry-resist precursors | Operational |
| EMEA channel restructuring | Announced 29 Dec 2025; effective 1 Jan 2026 | Nordmann takes full EMEA sales responsibility | Implemented |
| IBM High-NA EUV materials testing | Announced 5 Feb 2026 | IBM evaluates Gelest precursors on its EUV baseline process flows | Active |
| India market support | Announced 9 Feb 2026 | Nordmann India supports silanes, silicones and metal-organics, focus on coatings | Active |
| Thought-leadership at SPIE 2026 | Feb 2026 | Presentations on metal-oxide dry-resist precursors for High-NA EUV | Completed |
Medium-term targets
Gelest has published no financial targets. Parent-level: MCG's medium-term plan prioritises growth in Specialty Materials and semiconductors with increased investment there (Investor Day 2025 summary), which is directionally supportive of Gelest's precursor programme. Cost programmes, ESG targets or headcount targets specific to Gelest: not publicly disclosed. The only quantified operating target disclosed was the hiring plan for the new building (25+ initial hires, rising to as many as 50 production staff in Morrisville).
Products & Services
Gelest's catalogue runs to several thousand SKUs; pricing is by quotation and pack size and is not published as a model. The list below covers the named product families and named products identifiable from public sources. Launch years are given only where disclosed.
Silanes
| Product family | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Industrial silanes for adhesives, sealants, coatings and composites | Coupling agents that bond organic polymers to inorganic substrates (glass, metal, minerals) | Formulators of adhesives, sealants, coatings, composites | Named website product page |
| Silanes and silicones for epoxy resins | Silanes used to improve adhesion, moisture resistance and toughness in epoxy systems | Electronics encapsulation, composites, coatings | Named website page |
| Methyl silanes | Methyl-functional silane building blocks | Silicone and surface-treatment producers | Named website page |
| Acetylenic and alkynyl silanes | Silanes bearing C≡C groups for synthesis and click-type chemistry | Pharma/organic synthesis, materials R&D | Named website page; expanded range promoted by press release |
| Volatile higher silanes (perhydridooligosilanes) | Si–H oligosilanes used as low-temperature silicon deposition sources | Semiconductor and photovoltaic deposition | Named website page |
| Silylating agents / protecting groups | Reagents for pharmaceutical and fine-chemical synthesis | Pharma process chemists | Website bulk-reagents page |
| Surface-modification silanes | Hydrophobic/hydrophilic and functional surface treatments | Diagnostics, chromatography, medical device surfaces | NMC portfolio description |
| BIOSAFE HE4005 and HE4001 | Silane quaternary ammonium antimicrobials; marketed in 2021 as first methanol-free silane quats | Antimicrobial coatings, textiles, surfaces | Launched 5 Apr 2021 (MCA news) |
Silicones
| Product family | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Reactive silicone fluids (vinyl-, hydride-, silanol-, amino-, epoxy-functional) | Building blocks for addition- and condensation-cure silicone elastomers and modifiers | Medical device, electronics, coatings formulators | Core product line (website) |
| Ultra-high-viscosity silicone polymers / gums | Made using ultra-high-viscosity polymerisation capacity added in the capacity expansion | Elastomer compounders | Capacity-doubling article |
| Polyether-modified siloxanes | Surfactant-type silicones | Coatings, personal care | Gelest named as a participant in a 2026 market study (CB Insights news feed) |
| Treated micro-particles | Surface-modified particles from the dedicated surface-treatment operation | Cosmetics, coatings, fillers | Capacity-doubling article; directory specialties |
Metal-organics
| Product family | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Metal-organic catalysts and reagents | Metal alkoxides, alkyls and complexes used as catalysts in synthesis | Pharma and polymer chemists | Website |
| Bulk metal-organics for pharmaceutical and organic synthesis | Scale quantities of reagents | Pharma manufacturing | Named website page |
| ALD/CVD precursors | Silicon, silicon-carbon, silicon-nitride and metal precursors for thin films | Semiconductor fabs, tool makers | 2022 research reports (SiCxNy from tri(isopropyl)cyclotrisilazane; trisilacyclohexane for SiC) |
| EUV dry-resist metal-organic precursors | Metal-oxide resist precursors for Lam's dry-resist process and High-NA EUV | Lam Research ecosystem, logic and DRAM fabs, IBM Research | Supply/R&D since Jul 2022; dedicated building opened May 2025 |
Acrylates and specialty monomers (Bimax)
| Product family | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Specialty acrylic and methacrylic monomers | Monomers for optical, electronic and industrial resins | Coatings, adhesives, latex makers | Bimax, acquired Jul 2019 |
| Vision-care monomers | Monomers used in contact lenses and intraocular lenses | Contact-lens and IOL manufacturers | CHEManager, Jul 2019 |
| Specialty surfactants and polymers | Used in personal care, water purification and pharmaceuticals | Personal care and pharma formulators | Circuits Assembly; CB Insights Bimax profile |
Services
| Service | Description |
|---|---|
| Custom synthesis and scale-up | Customer-specific molecules taken from lab to commercial scale |
| Technical service and literature | Extensive application literature and a Technical Library on the website |
| Quality-controlled electronic-grade manufacturing | ISO 7 cleanroom (≈3,000 sq ft / 275 m²) with analytical instrumentation in the 2025 building |
Financial Narrative
Disclosure position
Gelest has never been a public filer, and since 2020 its results are consolidated within Mitsubishi Chemical Group without disclosure. Neither MCG nor Gelest publishes Gelest revenue, profit, assets, debt or cash flow. One third-party sales-intelligence directory (Clodura, Nov 2025) lists revenue of USD 35M; this is a modelled estimate of unknown method, is inconsistent with a ~240-person specialty manufacturer that a strategic buyer chose to acquire, and is not adopted here. A separate investor-profile site states plainly that Gelest does not disclose revenue or profit figures.
Income statement, balance sheet, cash flow and ratios
All values: not publicly disclosed (blank cells).
Parent-level context (Mitsubishi Chemical Group)
Because Gelest is consolidated inside MCG's Specialty Materials segment, the parent's segment trajectory is the closest observable proxy for the environment Gelest operates in — but it is dominated by much larger businesses (performance polymers, films, carbon fibre, coating materials) and says nothing directly about Gelest.
Indirect indicators of Gelest's financial trajectory
Although no figures exist, several observable facts bound the trend qualitatively:
Capital deployment is rising, not falling: MCG funded a new 50,000 sq ft production building with a cleanroom (groundbreaking July 2023, opening May 2025). Parents in portfolio-restructuring mode — which MCG has been since 2024 — do not typically fund greenfield capacity in units they consider underperforming.
Commissioning slipped roughly eight months: (target Sept 2024, opened May 2025), which implies the capital spend was back-end loaded into FY2024–FY2025 and that revenue from the new building would only begin contributing in FY2025–FY2026.
Go-to-market restructuring in EMEA: (handing full EMEA sales to Nordmann from January 2026) is consistent with optimising selling costs in lower-density regions.
Revenue CAGR, margins, leverage: cannot be computed. Any analyst requiring these must source them from MCG management directly or from MCG's purchase-price allocation notes (if ever disclosed in Japanese securities reports).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Role |
|---|---|---|
Ultimate parent | Mitsubishi Chemical Group Corporation (Tokyo) | Listed holding company (TSE 4188) |
Operating parent (Japan) | Mitsubishi Chemical Corporation | Core chemical operating company |
US parent | Mitsubishi Chemical America, Inc. | Acquirer and 100% owner since 1 Oct 2020 |
Holding | Gelest Intermediate Holdings, Inc. | Acquired holding entity |
Operating company | Gelest, Inc. | Morrisville HQ and plants |
Operating site / brand | Bimax (Glen Rock, PA) | Specialty monomers and polymers; continued under Bimax name after 2019 |
Internal Business Details
| Internal business (inferred) | Contents | Evidence |
|---|---|---|
Silanes | Functional and non-functional organosilanes, coupling agents, silylating agents, volatile higher silanes | Website; 2015-era "Product Manager Silanes and Metal-Organics" role |
Silicones | Reactive silicone fluids, gums, high-viscosity polymers, treated micro-particles | Website; capacity-doubling article (Matt Edison, Silicones business manager) |
Metal-organics | Catalysts, reagents, ALD/CVD and EUV dry-resist precursors | Website; Lam/IBM collaborations |
Acrylates / specialty monomers (Bimax) | Specialty acrylic monomers and polymers for lenses, coatings, adhesives, personal care | Bimax acquisition releases |
Incubation / new technology R&D | Early-stage programmes such as dry-resist precursors | Li Yang, "R&D manager, incubation" (Feb 2026 release) |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Financial Analysis (2)
| Item | Detail | Source |
|---|---|---|
Specialty Materials core operating income | Third-party summary of MCG Investor Day 2025 reports a path from 239 oku yen (≈JPY 23.9bn) in FY2024 to a FY2029 target cited as 1,440 oku yen. The magnitude of that jump looks inconsistent with other MCG disclosures and may be a transcription error in the summary; verify against MCG's own Investor Day deck before use | Quartr event summary |
Q3 FY2025 (reported Feb 2026) | Specialty Materials profits rose despite lower revenue, attributed to rationalisation and higher selling prices; group structural reforms continuing (exit from carbon/coke, petrochemicals and MMA reviews) | AlphaSpread summary of MCG Q3 call |
Group profitability (TTM, early 2026) | Net margin ≈1.66%, ROE ≈3.18% (third-party data) | MarketBeat |
Capital Markets
| Item | Gelest | Parent (MCG) reference |
|---|---|---|
Dividend history / policy | Not applicable (any upstream dividends to MCA not disclosed) | — |
Transaction valuation reference | 2017 NMC entry and 2020 MCG exit values both undisclosed | — |
Metric | FY2021 | FY2022 |
Analyst Conclusions
Guidance and consensus
There is no Gelest guidance and no consensus. The relevant forward signals are qualitative: management says the new building exists to meet growing demand in microelectronics and medical devices; MCG says it will increase investment in Specialty Materials; and Gelest's two named semiconductor partners (Lam and IBM) have both publicly committed to High-NA EUV dry-resist development through 2026.
Bull case
-
Dry resist becomes a high-volume process. Lam's dry resist is backed by IBM's March 2026 expanded collaboration and earlier SK hynix DRAM adoption of Lam's dry-resist underlayer/development steps; if it scales, Gelest is one of only two named precursor suppliers and now has dedicated cleanroom capacity.
-
US on-shoring premium. A US-made, high-purity precursor source with a Japanese strategic parent is well placed under supply-chain-security procurement preferences.
-
Diversified, sticky base business. Vision-care monomers, medical silicones and pharma reagents are qualification-locked and less cyclical, funding the semiconductor bet.
Bear case
-
Technology concentration. The marquee capex is tied to one lithography route that still competes with spin-on metal-oxide resists; slower High-NA ramps would leave capacity underused.
-
Sub-scale against giants and its own partner. Entegris and integrated silicone producers can out-invest Gelest on purity, scale and global footprint.
-
Parent prioritisation risk. MCG is in the middle of a large restructuring; a small, undisclosed US unit could be reorganised, merged into a larger division or, in a downside scenario, divested.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Any disclosure of IBM test outcomes or follow-on agreements | Validation of Gelest precursors for High-NA |
| Lam dry-resist adoption announcements by DRAM/logic makers | Volume pull-through for precursors |
| Hiring at Morrisville toward the 50-person target | Proxy for utilisation of the new building |
| MCG FY2026 results and segment commentary on semiconductor materials | Only financial window onto Gelest |
| Nordmann EMEA/India commercial traction | Test of the distributor model |
| Leadership announcements | Stability after 2017–2022 churn |
| New patent grants in deposition and resist chemistry | IP depth |
Analyst verdict
Gelest is a high-quality but opaque asset whose public record supports a clear qualitative thesis and almost no quantitative one. The facts that can be verified point in a consistent direction. The company has a 35-year franchise in organosilicon and metal-organic specialty chemistry built by a recognised technical founder. It was bought by a growth-oriented private-equity owner in 2017, enlarged by the Bimax acrylates acquisition in 2019, and sold to Mitsubishi Chemical in 2020 for an undisclosed price after only three and a half years — itself evidence that a strategic buyer valued it highly. Under MCG, management has been technical and internally promoted, and the parent has committed real capital: a 50,000 sq ft building with a cleanroom on a revitalised brownfield, opened in May 2025.
Strategically, Gelest has deliberately repositioned from a broad catalogue house toward a semiconductor-materials supplier. Its partnerships with Lam Research and Entegris (2022) and IBM (2026) place it inside the leading ecosystem for EUV dry resist, and the March 2026 IBM–Lam High-NA announcement strengthens the demand thesis. The base businesses — vision-care monomers, medical silicones, pharma reagents and industrial silanes — are qualification-intensive and likely provide steady cash generation, although that cannot be demonstrated from public data.
The risks are equally clear: technology-route concentration, small scale against integrated giants (including a partner that is also a competitor), single-country manufacturing, a commissioning delay, and dependence on a parent in the middle of deep restructuring.
Net assessment: Gelest is strategically well positioned and appears to be in an investment phase within the part of MCG the parent has said it will grow. For counterparties — customers, suppliers, partners or potential acquirers — the decisive diligence items are not public: revenue scale, segment margins, customer concentration, and utilisation of the new building. Any engagement should begin by obtaining those directly from Gelest or MCG management.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education | Source |
|---|---|---|---|---|
Dr. Jonathan Goff | CEO/President, Gelest; MCG Business Vice President, Advanced Solutions Domain (2025); earlier VP, Custom Synthesis Division (2023) | Joined ~2009; CTO before becoming President on 3 Jan 2022; company page now calls him a 20-year veteran (conflicts with the "13-year veteran" description in Jan 2022, which implies ~17 years by 2026) | PhD, Macromolecular Science & Engineering, Virginia Tech; 60+ patents and publications | Gelest releases; leadership page |
Edward (Ed) Kimble | Senior Business Director / General Manager (2025); EVP commercial from Jan 2022 | 20+ years at Gelest; previously SVP Product Management | Pennsylvania State University | Newswire (Jan 2022); ICN (May 2025) |
William (Bill) Fry | CFO (appointed Jan 2022) | Joined Gelest 2010; prior public accounting | CPA; West Chester University | Newswire, Jan 2022 |
Eric Strating | Commercial Director | Previously Global Commercial Director at Sustainable Materials, Commercial Director at Material Solutions; earlier roles at Zestron, Eastman Chemical, Edmund Optics | — | Leadership page; Nordmann release |
Jen Predmore | Senior Manager, HR Business Partner | Joined 2015 as HR Manager; earlier HR roles in microelectronics manufacturing | — | Leadership page |
Amanda (surname not shown in retrieved excerpt) | Senior Manager, Customer Experience | Leads customer service; sits on leadership team | — | Leadership page |
Jinping (surname not shown in retrieved excerpt) | Leadership-team member (title not shown in excerpt) | ~10 years in specialty chemicals | — | Leadership page |
Allison Bezden | Spokesperson on IBM collaboration (title not shown in retrieved excerpt) | — | — | IBM release, Feb 2026 |
Dr. Li Yang | R&D Manager, Incubation | Presenter on metal-oxide dry-resist precursors at SPIE Advanced Lithography 2026 | PhD | IBM release coverage |
Dr. Santy (first name not in retrieved excerpt) | Promoted Jan 2022 from Senior Manager, Silicones R&D | Joined 2012 | PhD | Newswire, Jan 2022 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Nov 2017 | Ken Gayer appointed CEO; Arkles to CTO & Chairman | Professionalisation under PE ownership |
12 Oct 2020 | Gayer resigns; Arkles reappointed CEO | Eleven days after Mitsubishi closing — continuity during integration |
31 Dec 2021 | Arkles retires as CEO | Joins Temple University as Distinguished Adjunct Professor |
3 Jan 2022 | Goff named President | Internal technical successor |
10 Jan 2022 | Kimble EVP, Fry CFO, Santy promoted | New leadership bench |
2023–2025 | Goff takes on MCG-level divisional titles | Deeper integration into MCG structure |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Mitsubishi Chemical America, Inc. (MCG) | 100% | MCC completion release, Oct 2020 |
Insider / management ownership | None post-2020 (founder and management had held a significant minority stake under NMC, 2017–2020) | CHEManager, Jul 2019 |
Competitive Landscape
Key Competitors
| Competitor | Where it competes with Gelest | Scale (approx.; latest FY) | Relative positioning |
|---|---|---|---|
Shin-Etsu Chemical | Silanes, silicones, semiconductor materials | Group sales ≈ JPY 2.5 trillion (FY to Mar 2025) | Integrated giant; far larger, upstream-integrated |
Dow (Dow Silicones) | Silanes, silicones (medical, electronics, personal care) | Group sales ≈ USD 43bn (2024) | Integrated; broad commodity-to-specialty |
Wacker Chemie | Silanes, silicones | Sales ≈ EUR 5.7bn (2024) | Integrated; strong in silanes for construction/adhesives |
Momentive Performance Materials | Silanes, specialty silicones | Private; not disclosed | Integrated; strong silane coupling-agent franchise |
Evonik (Dynasylan) | Functional silanes, specialty acrylates | Sales ≈ EUR 15bn (2024) | Large specialty; overlaps in coupling agents and methacrylates |
Elkem | Silicones | — | Integrated, cost-focused |
Entegris | Semiconductor precursors (also Gelest's partner in Lam ecosystem) | Revenue ≈ USD 3.2bn (2024) | Co-supplier and competitor for dry-resist precursors |
Merck KGaA (EMD Electronics, incl. former Versum) | ALD/CVD precursors | — | Leading deposition-precursor supplier |
Air Liquide (electronics materials) | Advanced precursors | — | Major precursor supplier |
Inpria (JSR) | Metal-oxide EUV resists (spin-on, alternative to dry resist) | — | Competing technology route rather than direct molecule rival |
MilliporeSigma (Sigma-Aldrich) | Research-quantity catalogue chemicals | Part of Merck KGaA | Broader catalogue, less organosilicon depth |
Avantor (NuSil) | Medical-grade silicones | — | Strong in implant-grade silicones |
Silok, Siltech and other specialty silicone houses | Specialty silicones | Private | Niche peers (CB Insights lists Silok as a competitor) |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Shin-Etsu | Wacker | Entegris |
|---|---|---|---|
Revenue | ≈JPY 2.5tn | ≈EUR 5.7bn | ≈USD 3.2bn |
Recent Developments
Parent and ecosystem events that bear directly on Gelest are included and labelled.
